Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid

Gastroenterology

Volumn 106, Issue 1, 1994, Pages 134-142

  Jazrawi, Riadh P ^a   De Caestecker, John S ^a   Goggin, Patrick M ^a   Britten, Alan J ^a   Joseph, Anton E A ^a   Maxwell, J Douglas ^a   Northfield, Tim C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAUROSELCHOLIC ACID SE 75; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; INTRAHEPATIC CHOLESTASIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; LIVER NECROSIS; LIVER SCINTISCANNING; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0028084463     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(94)94899-2     Document Type: Article

References (43)

1. Ursodeoxycholic acid for primary biliary cirrhosis
2. Update on primary biliary cirrhosis
3. Solubilisation of lipids from hamster bile canalicular and contiguous membranes and from human erythrocyte membranes by conjugated bile salts
4. Hepatoprotective effect of ursodeoxycholic acid in experimental animals
5. Enterohepatic circulation in man of a gamma-emitting bile acid conjugate, 23-selena-25-homocholic acid (SeHCAT)
6. 14C] taurocholate
7. Direct measurement of first-pass ileal clearance of a bile acid in humans
8. Tc-99m-labeled N-2,6-dimethyl phenyl carbamoylmethyl iminodiacetic acid (Tc-99m-HIDA): a new pharmaceutical for hepatobiliary studies
9. A new pharmaceutical for hepatobiliary imaging
10. The clinical role of Tc-99m imidodiacetic acid cholescintigraphy
11. Radiopharmaceuticals for hepatobiliary imaging
12. 75SeHCAT)
13. Ursodeoxycholic acid in liver disease
14. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
15. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
16. Ursodeoxycholic acid in primary biliary cirrhosis
17. Improvement of biliary enzyme levels and itching as a result of long term administration of ursodeoxycholic acid in primary biliary cirrhosis
18. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis
19. Ursodeoxycholic acid in primary biliary cirrhosis: results of a double blind controlled trial
20. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: interim analysis of a double blind multicentre randomised trial
21. Ursodeoxycholic acid for primary sclerosing cholangitis
22. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis
23. Ursodeoxycholate reduces toxicity of bile salts in primary human hepatocyte
24. Conjugates of ursodeoxecholate protect against cytotoxicity of more hydrophobic bile salts: In vitro of rat hepatocytes and human erythrocytes
25. Difference in the effect of ursodeoxycholate and its taurine conjugate on biliary excretion of bromsulphthalein in the rat
26. Influence of ursodeoxycholic acid on bile secretion
27. Mechanism of ursodeoxycholic-acid and canrenoate-induced bicarbonate secretion and the effect of glucose and amino acid induced cholestasis
28. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration
29. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis
30. Primary biliary cirrhosis
31. Assessment of activity of chronic active liver disease
32. Mechanism of cholestasis. VI. Bile acids in human livers with and without biliary obstruction
33. Effect of ursodeoxycholic acid on biliary lipid metabolism in primary biliary cirrhosis
34. Activation of mast cells by bile acids
35. Effect of hydrophilic and hydrophobic bile acids (BA) on human hepatocyte and erythrocyte membranes in vitro
36. Tauroursodeoxycholate prevents Taurocholate induced cholestasis
37. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis
38. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease
39. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis
40. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis
41. Acute effects of ursodeoxycholic acid and chenodeoxycholic acid on small intestinal absorption of bile acids
42. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses
43. Hepatic expression of class I and II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid